#ESMO26 #DeLLphi305 Tarlatamab 联合 Durvalumab 与 Durvalumab 单药治疗接受过铂类、Etoposide 和 Durvalumab 治疗的广泛期小细胞肺癌受试者
我们正在改变 SCLC 的预后吗？
是的，我们正在改变。
数据自会说明一切。
OS 21.1个月 vs 12.7个月
13 浏览 · 0 赞 · 0 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：David Heredia. · x.com